Natixis Advisors LLC Acquires 12,930 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Natixis Advisors LLC lifted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 18.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 81,877 shares of the company's stock after acquiring an additional 12,930 shares during the quarter. Natixis Advisors LLC owned about 0.06% of Henry Schein worth $5,969,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Cromwell Holdings LLC boosted its position in shares of Henry Schein by 93.4% in the third quarter. Cromwell Holdings LLC now owns 352 shares of the company's stock valued at $26,000 after acquiring an additional 170 shares during the period. Simplify Asset Management Inc. lifted its stake in Henry Schein by 5.0% during the second quarter. Simplify Asset Management Inc. now owns 3,695 shares of the company's stock worth $237,000 after purchasing an additional 175 shares during the period. Sequoia Financial Advisors LLC grew its stake in shares of Henry Schein by 3.2% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 5,680 shares of the company's stock valued at $364,000 after purchasing an additional 176 shares during the period. Studio Investment Management LLC grew its stake in shares of Henry Schein by 4.7% in the 2nd quarter. Studio Investment Management LLC now owns 4,502 shares of the company's stock valued at $289,000 after purchasing an additional 204 shares during the period. Finally, Mather Group LLC. lifted its position in shares of Henry Schein by 16.8% during the 2nd quarter. Mather Group LLC. now owns 1,502 shares of the company's stock worth $96,000 after buying an additional 216 shares during the period. Institutional investors and hedge funds own 96.62% of the company's stock.

Henry Schein Stock Performance

NASDAQ:HSIC traded up $1.31 during mid-day trading on Friday, reaching $75.08. 3,384,464 shares of the company's stock were exchanged, compared to its average volume of 1,902,142. Henry Schein, Inc. has a one year low of $63.67 and a one year high of $82.63. The business's fifty day simple moving average is $70.89 and its two-hundred day simple moving average is $69.76. The firm has a market capitalization of $9.36 billion, a PE ratio of 30.90, a price-to-earnings-growth ratio of 2.12 and a beta of 0.87. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.05. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.17 billion for the quarter, compared to analysts' expectations of $3.24 billion. During the same quarter last year, the business earned $1.32 earnings per share. Henry Schein's revenue was up .4% on a year-over-year basis. Analysts anticipate that Henry Schein, Inc. will post 4.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HSIC has been the subject of several recent analyst reports. Evercore ISI raised their price objective on shares of Henry Schein from $70.00 to $74.00 and gave the stock an "in-line" rating in a report on Tuesday, October 8th. Barrington Research reaffirmed an "outperform" rating and issued a $82.00 price target on shares of Henry Schein in a research note on Wednesday, November 6th. StockNews.com raised shares of Henry Schein from a "sell" rating to a "hold" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lowered their price objective on shares of Henry Schein from $88.00 to $80.00 and set an "overweight" rating for the company in a research report on Monday, August 12th. Finally, Robert W. Baird decreased their target price on Henry Schein from $92.00 to $82.00 and set an "outperform" rating for the company in a research note on Wednesday, August 7th. Six research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $78.89.

Insider Buying and Selling

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the transaction, the senior vice president now directly owns 71,833 shares of the company's stock, valued at approximately $4,978,026.90. The trade was a 22.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael S. Ettinger sold 12,240 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $75.00, for a total transaction of $918,000.00. Following the sale, the chief operating officer now directly owns 87,706 shares of the company's stock, valued at $6,577,950. This represents a 12.25 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.